RT Journal Article
SR Electronic
T1 CDX2 Is a Prognostic Biomarker for Unresectable Metastatic Colorectal Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3763
OP 3767
DO 10.21873/anticanres.16561
VO 43
IS 8
A1 MUKOHYAMA, JUNKO
A1 AGAWA, KYOSUKE
A1 YAMASHITA, KIMIHIRO
A1 MATSUDA, TAKERU
A1 SHINODA, MASAHIRO
A1 ITANO, OSAMU
A1 KAKEJI, YOSHIHIRO
YR 2023
UL http://ar.iiarjournals.org/content/43/8/3763.abstract
AB Background/Aim: Colorectal cancer (CRC) with reduced expression of the homeobox transcription factor CDX2, a master gene essential for the development and maintenance of the intestinal tract, is known as a poor prognosis subtype of CRC. The recurrence rate is high in patients with CDX2low CRC. However, the prognostic significance of CDX2 in advanced CRC is unclear. This study aimed to elucidate the prognostic significance of CDX2 in unresectable metastatic CRC (mCRC). Patients and Methods: Twenty-nine patients with unresectable mCRC who underwent primary site resection at the Kobe University Hospital during a 6-year period from January 2008 to January 2015 were included. The tissues from those patients were immunohistochemically stained with anti-CDX2 antibody (clone: CDX2-88). The patients were divided into CDX2high CRC group and CDX2low CRC group and their prognoses were analyzed. Results: There were no clear differences in background between the two groups. A low CDX2 expression was associated with reduced overall survival (37.67 months vs. 25.32 months, p=0.03) and tended to associate with reduced progression-free survival (17.4 months vs. 12.9 months, p=0.37). Two patients received chemotherapy after resection of the primary lesion and obtained pathological complete response. Conclusion: CDX2 expression might be a possible prognostic biomarker for unresectable mCRC.